I would have to see when the failures occurred. If most failures occurred before week 4, then whatever reason, giving leronlimab the first week before switching HAART drugs really makes a difference. If they occurred after week 4, then just a weird coincidence. One reason this could be an issue, I personally don’t think they should start counting failures until leronlimab is fully into their system and the non-placabo group got a two week headstart, which made me think it could be similar to the overlap issue with mono.